ArticleJournal of virology2004
APOBEC3G targets specific virus species.
Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature.Microbiology and molecular biology reviews : MMBR · 2018Pooled it
- Herpes simplex virus 1 evades APOBEC1-mediated immunity via its uracil-DNA glycosylase in mice.Nature microbiology · 2025Article
- Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1.Retrovirology · 2019Review
- Structural Determinants of the APOBEC3G N-Terminal Domain for HIV-1 RNA Association.Frontiers in cellular and infection microbiology · 2019Article
- APOBEC3-mediated restriction of RNA virus replication.Scientific reports · 2018Article
- Core Binding Factor β Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation.The Journal of biological chemistry · 2016Article
- How Active Are Porcine Endogenous Retroviruses (PERVs)?Viruses · 2016Review
- Small molecules that inhibit Vif-induced degradation of APOBEC3G.Virology journal · 2014Article
- Different modes of retrovirus restriction by human APOBEC3A and APOBEC3G in vivo.PLoS pathogens · 2014Article
- Transgenic expression of the human LEDGF/p75 gene relieves the species barrier against HIV-1 infection in mouse cells.Frontiers in microbiology · 2013Article
- APOBEC3G oligomerization is associated with the inhibition of both Alu and LINE-1 retrotransposition.PloS one · 2013Article
- The APOBEC3 family of retroelement restriction factors.Current topics in microbiology and immunology · 2013Review
- An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals.BMC evolutionary biology · 2012Article
- Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses.Clinical microbiology reviews · 2012Review
- Retroelements versus APOBEC3 family members: No great escape from the magnificent seven.Frontiers in microbiology · 2012Article
- Restriction of porcine endogenous retrovirus by porcine APOBEC3 cytidine deaminases.Journal of virology · 2011Article
- The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3.Journal of virology · 2010Article
- Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity.Journal of virology · 2010Article
- Apobec 3G efficiently reduces infectivity of the human exogenous gammaretrovirus XMRV.PloS one · 2010Article
- Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.Journal of virology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human APOBEC3G (huAPOBEC3G), also known as CEM15, is a broad antiretroviral host factor that deaminates dC to dU in the minus strand DNA of human immunodeficiency virus type 1 (HIV-1), other lentiviruses, and murine leukemia virus (MLV), thereby creating G-to-A hypermutation in the plus strand DNA to inhibit the infectivity of these viruses. In this study, we examined the antiretroviral function of a murine homologue of APOBEC3G (muAPOBEC3G) on several retrovirus systems with different producer cells. MuAPOBEC3G did not suppress the infectivity of murine retroviral vectors produced from human or murine cells, whereas it showed antiviral activity on both wild-type and Deltavif virions of HIV-1 in human cells. In contrast, huAPOBEC3G showed broad antiviral activity on HIV-1 and murine retroviral vectors produced from human cells as well as murine cells. These data suggested that muAPOBEC3G does not possess antiretroviral activity on murine retroviruses and has a different target specificity from that of huAPOBEC3G and that huAPOBEC3G works as a broad antiviral factor not only in human cells but also in murine cells. A functional interaction study between human and murine APOBEC3G supported the former hypothesis. Furthermore, studies on the expression of APOBEC3G in producer cells and its incorporation into virions revealed that muAPOBEC3G is incorporated into HIV-1 virions but not into MLV virions. Thus, muAPOBEC3G cannot suppress the infectivity of murine retrovirus because it is not incorporated into virions. We suggest that murine retroviruses can replicate in murine target cells expressing muAPOBEC3G because they are not targets for this enzyme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.